|
DE2236930A1
(de)
|
1971-08-03 |
1973-02-15 |
Cameroun Etat |
Verfahren zur herstellung von desmosterol
|
|
GB1447456A
(en)
|
1973-06-20 |
1976-08-25 |
Teijin Ltd |
Process for preparing desmosterols
|
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
|
DE3823318A1
(de)
|
1988-07-09 |
1990-02-22 |
Bayer Ag |
(hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
|
|
US5229115A
(en)
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
|
IE68836B1
(en)
|
1991-01-16 |
1996-07-10 |
Schering Corp |
Use of interleukin-10 in adoptive immunotherapy of cancer
|
|
TW263508B
(enExample)
|
1991-02-12 |
1995-11-21 |
Pfizer |
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
JP3414433B2
(ja)
|
1993-03-01 |
2003-06-09 |
日本化薬株式会社 |
電子写真用トナー
|
|
DE19523446A1
(de)
|
1995-06-28 |
1997-01-02 |
Bayer Ag |
Benzotriazole
|
|
AU6490396A
(en)
|
1995-07-14 |
1997-02-18 |
Smithkline Beecham Corporation |
Substituted-pent-4-ynoic acids
|
|
BR9609888A
(pt)
|
1995-08-10 |
1999-05-25 |
Bayer Ag |
Halogenobenzimidazóis
|
|
HUP9900625A3
(en)
|
1995-12-28 |
2003-04-28 |
Fujisawa Pharmaceutical Co |
Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds
|
|
NZ332073A
(en)
*
|
1996-03-29 |
2000-05-26 |
Dimensional Pharm Inc |
Substituted hydrazinecarboximines as non-peptidic protease inhibitors
|
|
WO1997048697A1
(en)
|
1996-06-19 |
1997-12-24 |
Rhone-Poulenc Rorer Limited |
Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
|
|
ES2215242T3
(es)
|
1996-11-19 |
2004-10-01 |
Amgen Inc. |
Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
|
|
US6392010B1
(en)
|
1996-12-19 |
2002-05-21 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
JP4327915B2
(ja)
|
1998-03-30 |
2009-09-09 |
株式会社デ・ウエスタン・セラピテクス研究所 |
スルフォンアミド誘導体
|
|
JP2002527359A
(ja)
|
1998-09-18 |
2002-08-27 |
ビーエーエスエフ アクチェンゲゼルシャフト |
キナーゼインヒビターとしての４−アミノピロリピリミジン
|
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
|
US6316503B1
(en)
|
1999-03-15 |
2001-11-13 |
Tularik Inc. |
LXR modulators
|
|
AU6762400A
(en)
|
1999-08-12 |
2001-03-13 |
Cor Therapeutics, Inc. |
Inhibitors of factor xa
|
|
EP1741428A3
(en)
|
1999-08-13 |
2007-05-09 |
Biogen Idec MA, Inc. |
Cell adhesion inhibitors
|
|
WO2001021577A2
(en)
|
1999-09-20 |
2001-03-29 |
Takeda Chemical Industries, Ltd. |
Melanin concentrating hormone antagonist
|
|
AU2001285018A1
(en)
|
2000-08-17 |
2002-02-25 |
Agensys, Inc. |
Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
|
|
TWI239942B
(en)
|
2001-06-11 |
2005-09-21 |
Dainippon Pharmaceutical Co |
N-arylphenylacetamide derivative and pharmaceutical composition containing the same
|
|
ATE515495T1
(de)
|
2001-08-03 |
2011-07-15 |
Schering Corp |
Gamma sekretase inhibitoren
|
|
DE60232981D1
(de)
|
2001-08-17 |
2009-08-27 |
Sankyo Agro Co Ltd |
3-phenoxy-4-pyridazinolderivat und dieses enthaltende herbizide zusammensetzung
|
|
WO2003104428A2
(en)
|
2002-01-21 |
2003-12-18 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
|
DE10229777A1
(de)
|
2002-07-03 |
2004-01-29 |
Bayer Ag |
Indolin-Phenylsulfonamid-Derivate
|
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
|
US6894061B2
(en)
|
2002-12-04 |
2005-05-17 |
Wyeth |
Substituted dihydrophenanthridinesulfonamides
|
|
UA80171C2
(en)
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
|
JP2006512357A
(ja)
|
2002-12-20 |
2006-04-13 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
Ｐｉ３ｋの阻害剤としてのベンゾキサジンおよびその誘導体
|
|
JP4601038B2
(ja)
|
2003-03-26 |
2010-12-22 |
第一三共株式会社 |
インドリルマレイミド類
|
|
US20080199486A1
(en)
|
2003-05-12 |
2008-08-21 |
Yair Argon |
Grp94-based compositions and methods of use thereof
|
|
EP2145888A1
(en)
|
2003-09-18 |
2010-01-20 |
Conforma Therapeutics Corporation |
Deazapurine derivatives as HSP90-Inhibitors
|
|
WO2005033048A2
(en)
|
2003-09-29 |
2005-04-14 |
The Johns Hopkins University |
Wnt pathway antagonists
|
|
WO2005033288A2
(en)
|
2003-09-29 |
2005-04-14 |
The Johns Hopkins University |
Hedgehog pathway antagonists
|
|
SE0302760D0
(sv)
|
2003-10-20 |
2003-10-20 |
Biovitrum Ab |
New compounds
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
AU2004299201B2
(en)
|
2003-12-09 |
2009-12-03 |
F. Hoffmann-La Roche Ag |
Benzoxazine derivatives and uses thereof
|
|
DE602004025504D1
(de)
|
2003-12-23 |
2010-03-25 |
Novartis Ag |
Bicyclische heterocyclische p-38-kinase-inhibitoren
|
|
WO2005084208A2
(en)
|
2004-02-27 |
2005-09-15 |
New York University |
A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
|
|
WO2005120558A2
(en)
|
2004-05-25 |
2005-12-22 |
University Of Connecticut Health Center |
Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
|
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
|
CA2572334A1
(en)
|
2004-07-01 |
2006-01-19 |
New York University |
Compositions and methods for modulation of ror.gamma.t
|
|
FR2874011B1
(fr)
|
2004-08-03 |
2007-06-15 |
Sanofi Synthelabo |
Derives de sulfonamides, leur preparation et leur application en therapeutique
|
|
US20070010537A1
(en)
|
2004-08-20 |
2007-01-11 |
Kazumasa Hamamura |
Fused pyramidine derivative and use thereof
|
|
US7304073B2
(en)
|
2004-08-20 |
2007-12-04 |
Wyeth |
Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
|
|
US7652043B2
(en)
|
2004-09-29 |
2010-01-26 |
The Johns Hopkins University |
WNT pathway antagonists
|
|
PT1809321E
(pt)
|
2004-10-08 |
2012-05-17 |
Us Gov Health & Human Serv |
Imunoterapia adotiva com sobrevivência aumentada de linfócitos
|
|
PT1814580T
(pt)
|
2004-11-24 |
2016-11-11 |
Hutchinson Fred Cancer Res |
Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
|
|
AR051780A1
(es)
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
|
GB0514911D0
(en)
|
2005-07-20 |
2005-08-24 |
Univ Birmingham |
T cell memory assay
|
|
ATE517883T1
(de)
|
2005-08-25 |
2011-08-15 |
Schering Corp |
Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors
|
|
US8003624B2
(en)
|
2005-08-25 |
2011-08-23 |
Schering Corporation |
Functionally selective ALPHA2C adrenoreceptor agonists
|
|
ATE543813T1
(de)
|
2005-09-01 |
2012-02-15 |
Janssen Pharmaceutica Nv |
Neue benzopyranderivate als kaliumkanalöffner
|
|
WO2007031429A1
(en)
|
2005-09-15 |
2007-03-22 |
F. Hoffmann-La Roche Ag |
Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase
|
|
FR2896798A1
(fr)
|
2006-01-27 |
2007-08-03 |
Sanofi Aventis Sa |
Derives de sulfonamides, leur preparation et leur application en therapeutique
|
|
EP1996563B1
(en)
|
2006-02-13 |
2012-03-21 |
F. Hoffmann-La Roche AG |
Heterobicyclic sulfonamide derivatives for the treatment of diabetes
|
|
KR101411695B1
(ko)
|
2006-02-17 |
2014-07-03 |
리겔 파마슈티칼스, 인크. |
자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
|
|
MX2008011302A
(es)
|
2006-03-01 |
2008-11-04 |
Janssen Pharmaceutica Nv |
Tratamiento de cancer que combina agente de linfodeplecion con linfocitos t citotoxicos y citocinas.
|
|
CA2646093A1
(en)
|
2006-04-06 |
2007-10-11 |
Tibotec Pharmaceuticals Ltd. |
A homogeneous time resolved fluorescence based test system
|
|
CA2651072A1
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
|
US20080305169A1
(en)
|
2006-05-26 |
2008-12-11 |
Japan Tobacco Inc. |
Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
|
|
JP2009538910A
(ja)
|
2006-06-01 |
2009-11-12 |
ワイス |
５−ヒドロキシトリプタミン−６リガンドとしての１−スルホニルインダゾリルアミン誘導体および１−スルホニルインダゾリルアミド誘導体
|
|
EP2046741B1
(en)
|
2006-07-03 |
2012-10-31 |
Proximagen Ltd. |
Indoles as 5-ht6 modulators
|
|
US7973135B2
(en)
|
2006-07-12 |
2011-07-05 |
Oncotx, Inc. |
Compositions and methods for targeting cancer-specific transcription complexes
|
|
TWI315304B
(en)
|
2006-08-31 |
2009-10-01 |
Univ Taipei Medical |
Indoline-sulfonamides compounds
|
|
US8389739B1
(en)
|
2006-10-05 |
2013-03-05 |
Orphagen Pharmaceuticals |
Modulators of retinoid-related orphan receptor gamma
|
|
WO2008045664A2
(en)
|
2006-10-06 |
2008-04-17 |
Kalypsys, Inc. |
Heterocyclic pde4 inhibitors as antiinflammatory agents
|
|
WO2008062740A1
(fr)
|
2006-11-20 |
2008-05-29 |
Japan Tobacco Inc. |
Composé azoté à anneaux fusionnés et son utilisation
|
|
US7799933B2
(en)
|
2006-12-21 |
2010-09-21 |
Hoffman-La Roche Inc. |
Sulfonamide derivatives
|
|
US20080186971A1
(en)
|
2007-02-02 |
2008-08-07 |
Tarari, Inc. |
Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
|
|
WO2008150827A1
(en)
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
JP2010529843A
(ja)
|
2007-06-03 |
2010-09-02 |
オンコティーエックス インコーポレイテッド |
バイオマーカーおよび薬物標的としての、転写因子複合体の構成要素のがん関連アイソフォーム
|
|
US7776877B2
(en)
|
2007-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
|
|
US20110190280A1
(en)
|
2007-08-29 |
2011-08-04 |
George Adjabeng |
Thiazole And Oxazole Kinase Inhibitors
|
|
WO2009035997A2
(en)
|
2007-09-14 |
2009-03-19 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
|
EP2203746B1
(en)
|
2007-09-24 |
2013-03-06 |
Technion Research & Development Foundation Ltd. |
T cell subpopulations capable of treating cancer
|
|
RU2364597C1
(ru)
|
2007-12-14 |
2009-08-20 |
Андрей Александрович Иващенко |
ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
|
|
US7960377B2
(en)
|
2008-03-28 |
2011-06-14 |
Cara Therapeutics, Inc. |
Substituted pyridoxazines
|
|
ES2566339T3
(es)
|
2008-06-05 |
2016-04-12 |
Glaxo Group Limited |
Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
|
|
JP5502077B2
(ja)
|
2008-06-05 |
2014-05-28 |
グラクソ グループ リミテッド |
新規な化合物
|
|
ES2445199T3
(es)
|
2008-06-05 |
2014-02-28 |
Glaxo Group Limited |
Derivados de benzpirazol como inhibidores de PI3-quinasas
|
|
CA2727373A1
(en)
|
2008-06-09 |
2009-12-17 |
Sanofi-Aventis |
Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
|
|
EP2288605B1
(en)
|
2008-06-09 |
2014-06-25 |
Sanofi |
Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
|
|
WO2009157196A1
(ja)
|
2008-06-25 |
2009-12-30 |
武田薬品工業株式会社 |
アミド化合物
|
|
WO2010017827A1
(en)
|
2008-08-14 |
2010-02-18 |
European Molecular Biology Laboratory |
6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
|
|
WO2010030947A1
(en)
|
2008-09-11 |
2010-03-18 |
University Of Florida Research Foundation, Inc. |
System and method for producing t cells
|
|
PL2344471T3
(pl)
|
2008-10-02 |
2013-12-31 |
Taisho Pharmaceutical Co Ltd |
Pochodna 7-piperydynoalkilo-3,4-dihydrochinolonu
|
|
EP2181710A1
(en)
|
2008-10-28 |
2010-05-05 |
Phenex Pharmaceuticals AG |
Ligands for modulation of orphan receptor-gamma (NR1F3) activity
|
|
WO2010057101A2
(en)
|
2008-11-17 |
2010-05-20 |
Schering Corporation |
Compounds useful as hiv blockers
|
|
JP2012509274A
(ja)
|
2008-11-19 |
2012-04-19 |
シェーリング コーポレイション |
ジアシルグリセロールアシルトランスフェラーゼの阻害薬
|
|
JP5628828B2
(ja)
|
2008-12-19 |
2014-11-19 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
チアゾロピリジンサーチュイン調節化合物
|
|
TW201030007A
(en)
|
2009-02-06 |
2010-08-16 |
Gruenenthal Gmbh |
Substituted spiro-amides as b1r modulators
|
|
US8524751B2
(en)
|
2009-03-09 |
2013-09-03 |
GlaxoSmithKline Intellecutual Property Development |
4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
|
|
TW201102391A
(en)
|
2009-03-31 |
2011-01-16 |
Biogen Idec Inc |
Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
|
|
WO2010123139A1
(ja)
|
2009-04-24 |
2010-10-28 |
持田製薬株式会社 |
スルファモイル基を有するアリールカルボキサミド誘導体
|
|
CN102459253B
(zh)
|
2009-04-30 |
2015-03-25 |
葛兰素集团有限公司 |
作为pi3-激酶抑制剂的*唑取代的吲唑化合物
|
|
US9499627B2
(en)
|
2009-08-03 |
2016-11-22 |
University Of Miami |
Method for in vivo expansion of T regulatory cells
|
|
US8119683B2
(en)
|
2009-08-10 |
2012-02-21 |
Taipei Medical University |
Aryl substituted sulfonamide compounds and their use as anticancer agents
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
US9556201B2
(en)
|
2009-10-29 |
2017-01-31 |
Glaxosmithkline Llc |
Bicyclic pyridines and analogs as sirtuin modulators
|
|
US20120238559A1
(en)
|
2009-12-03 |
2012-09-20 |
Glaxo Group Limited |
Novel compounds
|
|
WO2011067366A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
|
EP2507223A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
US20110142814A1
(en)
|
2009-12-16 |
2011-06-16 |
New York University |
Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
|
|
EP3064204A1
(en)
|
2010-03-01 |
2016-09-07 |
GTx, Inc. |
Compounds for treatment of cancer
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
WO2011115892A1
(en)
*
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
WO2012032065A1
(en)
|
2010-09-08 |
2012-03-15 |
Glaxo Group Limited |
Indazole derivatives for use in the treatment of influenza virus infection
|
|
JP5965402B2
(ja)
|
2010-09-08 |
2016-08-03 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩
|
|
CN103491956A
(zh)
*
|
2010-09-13 |
2014-01-01 |
麦克罗拜奥提斯公司 |
病毒进入哺乳动物细胞的抑制剂
|
|
WO2012037108A1
(en)
|
2010-09-13 |
2012-03-22 |
Glaxosmithkline Llc |
Aminoquinoline derivatives as antiviral agents
|
|
JP6063870B2
(ja)
|
2010-11-08 |
2017-01-18 |
ライセラ・コーポレイション |
ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2487159A1
(en)
|
2011-02-11 |
2012-08-15 |
MSD Oss B.V. |
RorgammaT inhibitors
|
|
US9629910B2
(en)
|
2011-03-22 |
2017-04-25 |
The Brigham And Women's Hospital, Inc. |
Use of Th9 cells and IL-9 for the treatment of melanoma
|
|
RU2688185C2
(ru)
|
2011-03-23 |
2019-05-21 |
Фред Хатчинсон Кэнсер Рисерч Сентер |
Способ и композиции для клеточной иммунотерапии
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
EP2511263A1
(en)
|
2011-04-14 |
2012-10-17 |
Phenex Pharmaceuticals AG |
Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
|
|
US9586928B2
(en)
|
2011-05-16 |
2017-03-07 |
The Scripps Research Institute |
Modulators of the nuclear hormone receptor ROR
|
|
EP2723347B1
(en)
|
2011-06-24 |
2019-09-04 |
GRI Bio, Inc. |
Prevention and treatment of inflammatory conditions
|
|
ES2659455T3
(es)
|
2011-09-19 |
2018-03-15 |
ETH Zürich |
Moduladores del ROR gamma para tratar complicaciones de diabetes II
|
|
GB201116641D0
(en)
*
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
US9593314B2
(en)
|
2012-03-16 |
2017-03-14 |
Covagen Ag |
Binding molecules with antitumoral activity
|
|
KR20150013500A
(ko)
|
2012-05-08 |
2015-02-05 |
머크 샤프 앤드 돔 코포레이션 |
Ror감마 활성의 억제를 위한 비시클릭 술폰 화합물 및 질환의 치료
|
|
RU2014149136A
(ru)
|
2012-05-08 |
2016-07-10 |
Мерк Шарп И Доум Корп. |
ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
|
|
WO2013167136A1
(en)
|
2012-05-08 |
2013-11-14 |
Herlev Hospital |
Improving adoptive cell therapy with interferon gamma
|
|
WO2013169864A2
(en)
|
2012-05-08 |
2013-11-14 |
Lycera Corporation |
TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
|
|
JP6220388B2
(ja)
|
2012-05-25 |
2017-10-25 |
ヘルス・ダイアグノスティック・ラボラトリー，インコーポレーテッド |
ステロール／スタノール又はそれらの誘導体の迅速でハイスループットの分析
|
|
WO2014026330A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
WO2014026328A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014028669A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Biogen Idec Ma Inc. |
Novel compounds for modulation of ror-gamma activity
|
|
WO2014026329A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026327A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
|
|
US9758591B2
(en)
|
2012-08-24 |
2017-09-12 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
EP2931267A1
(en)
*
|
2012-12-17 |
2015-10-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
|
|
WO2014201378A1
(en)
|
2013-06-13 |
2014-12-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
|
|
US9783511B2
(en)
|
2013-12-20 |
2017-10-10 |
Lycera Corporation |
Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
|
|
US9663502B2
(en)
|
2013-12-20 |
2017-05-30 |
Lycera Corporation |
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
|
|
US9809561B2
(en)
|
2013-12-20 |
2017-11-07 |
Merck Sharp & Dohme Corp. |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
|
MX2016010998A
(es)
|
2014-02-27 |
2017-03-31 |
Lycera Corp |
Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
|
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
CA2982847A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
|